Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1017 results about "Bioactive peptide" patented technology

Biologically active dimerized and multimerized polypeptide fusions

Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
Owner:ZYMOGENETICS INC

Biologically active peptidomimetic macrocycles

The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Owner:AILERON THERAPEUTICS INC

Self-assembling peptides incorporating modifications and methods of use thereof

The invention provides a self-assembling peptide comprising (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not self-assemble in isolated form. In certain embodiments of the invention the second amino acid domain comprises a biologically active peptide motif, e.g., a peptide motif found in a naturally occurring protein, or a target site for an interaction with a biomolecule. In certain embodiments of the invention the naturally occurring protein is a component of the extracellular matrix, e.g., a component of the basement membrane. The invention further provides scaffolds comprising the self-assembling peptides and methods of using the scaffolds including for cell culture, tissue engineering, and tissue repair.
Owner:MASSACHUSETTS INST OF TECH

Peptidomimetic macrocycles with improved properties

The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Owner:AILERON THERAPEUTICS INC

Biologically Active Peptidomimetic Macrocycles

The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Owner:AILERON THERAPEUTICS INC

Therapeutic peptidomimetic macrocycles

InactiveUS20090275519A1Less treatmentReduce activated hPBL proliferationMetabolism disorderPeptidesMedicineBioactive peptide
The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.
Owner:AILERON THERAPEUTICS INC

Peptidomimetic macrocycles

The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Owner:AILERON THERAPEUTICS INC

Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Disclosed are peptide agents and uses thereof that are analogs of biologically active peptides such as somatostatin and bombesin. The compounds of the invention have the general formula X-Y-Z-Q, where X is a cytotoxic agent, therapeutic agent, detectable label or chelating group, and Q is a biologically active peptide. In peptide agents of the invention Y is optionally a hydrophilic polymer or peptide, and Z is a linking peptide bonded to Q at the amino terminus of Q, having two, three, four, or five, amino acid residues selected to link X to Q, while retaining the biological activity of Q. Methods of using these peptide agents in the diagnosis and treatment of diseases are also disclosed.
Owner:TULANE EDUCATIONAL FUND

Anti-wrinkle composition

A composition is disclosed for treating the skin comprising an acylated short chain bioactive peptide and Lycium barbarum extract product. Also disclosed is a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The composition may contain dimethylisosorbide or ethoxydiglycol as solubilizing and penetration enhancers for the hydrophobically modified peptide.
Owner:GRANT INDS

Biologically active peptidomimetic macrocycles

The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Owner:AILERON THERAPEUTICS INC

Anti-wrinkle cosmetic composition

The present invention relates to a composition for treating skin comprising an acylated short chain bioactive peptide and fulvic acid, and optionally colloidal gold. The invention further relates to a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The invention further relates to a method of treating wrinkled skin by topically administering the composition to an individual in need of such treatment.
Owner:GRANT INDS

Nutritional composition intended for specific gastro-intestinal maturation in premature mammals

A nutritional enteral composition intended for favoring the growth and maturation of non-mature gastro-intestinal tracts of young mammals, which contains as a protein source a mixture of dietary protein hydrolysates and intact proteins being partly in the form of bioactive peptides.
Owner:NESTEC SA

Biological feed additive rich in bioactive peptides and probiotics as well as preparation method of additive

InactiveCN105410337AHigh content of active peptidesHigh viable count of beneficial bacteriaFungiBacteriaMetaboliteBioactive peptide
The invention discloses a biological feed additive rich in bioactive peptides and probiotics as well as a preparation method of the additive. The biological feed additive prepared with the method has the peptide content higher than 20%, the active probiotic content up to 1.0*10<9> cfu / g and contains fermentation metabolites such as bacteriocin and the like; meanwhile, the additive has the advantages that the additive is purely natural, non-toxic, harmless and free of pollution and residues.
Owner:上海邦成生物工程有限公司

Stabilized bioactive peptides and methods of identification, synthesis, and use

InactiveUS20060099571A1Slow down rate of intracellular degradationBacteriaPeptide/protein ingredientsLac operonΑ helical
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.
Owner:PEPTIDE BIOSCI

Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20

Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP / DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and fusion polypeptide, expression vectors comprising such DNA, and cells expressing such polypeptides, or pharmaceutical compositions thereof, are useful for stimulating neural stem cell differentiation, maturation along the oligodendrocytic pathway and proliferation of oligodendrocytes or precursors. These compositions can protect oligodendrocytes (and nonneural cells) from apoptotic death. Thus, the present composition is used to treat a disease or condition in which such differentiation, maturation and proliferation or inhibition of cell death, including remyelination or stimulation of oligodendroglia or Schwann cells, is desirable. Disorders include multiple sclerosis, trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma.
Owner:WAYNE STATE UNIV

Process of continuous production of casein bioactive peptide by enzymolysis and filtering membrane concentration

The invention relates to a process of continuous production of casein bioactive peptide by enzymolysis and filtering membrane concentration which comprises, using caseinum as raw material and at least one prolease action, obtaining biologically active polypeptides having multiple functions in multi-stage enzyme membrane reactor combined from enzymolysis tank and hyperfiltration, nano filter membrane of dissimilar entrapment molecular weight.
Owner:TIANJIN UNIV

Casein-derived antioxidant peptide and preparation method thereof

The invention relates to the technical field of bioactive peptides, in particular to a casein-derived antioxidant peptide mixture. Casein is hydrolyzed with protease, various pre-products of the casein antioxidant peptide are obtained, then separation, desalination and concentration are performed through ion exchange column chromatography, and the casein antioxidant peptide rich in basic amino acid is obtained. The casein antioxidant peptide has higher cell antioxidant capacity and low-density lipoprotein oxidation inhibition capacity and can still keep good antioxidant capacity after being digested and absorbed by gastrointestinal tracts, so that the casein antioxidant peptide rich in basic amino acid can be applied to fields of food and healthcare products and has very high social and economic benefit.
Owner:CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products